Cargando…
Doctor reported outcomes: Real-world data from a tertiary eye cancer center
PURPOSE: To provide real-world data on the world-wide-web for patient and doctor awareness. METHODS: From December 2017 to January 2020, consecutive patients with choroidal melanoma (CM), iris ciliary body melanoma (ICM), and ocular surface squamous carcinoma (OSSC) had specific outcomes recorded at...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926100/ https://www.ncbi.nlm.nih.gov/pubmed/33323598 http://dx.doi.org/10.4103/ijo.IJO_257_20 |
_version_ | 1783659397557256192 |
---|---|
author | Maheshwari, Abhilasha Finger, Paul T Malpani, Abhishek Jain, Puneet Tomar, Ankit Singh Garg, Gaurav |
author_facet | Maheshwari, Abhilasha Finger, Paul T Malpani, Abhishek Jain, Puneet Tomar, Ankit Singh Garg, Gaurav |
author_sort | Maheshwari, Abhilasha |
collection | PubMed |
description | PURPOSE: To provide real-world data on the world-wide-web for patient and doctor awareness. METHODS: From December 2017 to January 2020, consecutive patients with choroidal melanoma (CM), iris ciliary body melanoma (ICM), and ocular surface squamous carcinoma (OSSC) had specific outcomes recorded at each return visit. Each result was anonymized, entered in an online portal, and sent to a unique software program where it was used to create real-world data of number of patients, mean vision, local tumor control, eye salvage, systemic metastases, and length of follow-up for our eye cancer center. RESULTS: A HIPAA compliant, internet-based software program was developed and linked to public access web page to collect and analyze near-real-time data pertaining to the treatment, vision, life, and follow-up time of patients. During this period, CM radiation plaque tumor control was 99.7%, median vision 20/25 (mean 20/50) and eye salvage 95.8%. ICM tumor control was 99.1% and the median vision 20/20 (mean 20/20). OSSC tumor control was 100% and the most common vision was 20/20 (mean 20/25). Rates of primary enucleation as treatment were 4.2% for CM, 2.8% for ICM, and 0% for OSSC. All patient results were updated by the ophthalmic oncology fellow at each patient visit as to reflect near-real-time outcomes at our center. CONCLUSION: Prospective data collection of returning patients was found to be a simple method to reflect patient care outcomes. This method of reporting doctor outcomes offers a measure of transparency for patients and an opportunity to compare results with other clinical practices. |
format | Online Article Text |
id | pubmed-7926100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-79261002021-03-05 Doctor reported outcomes: Real-world data from a tertiary eye cancer center Maheshwari, Abhilasha Finger, Paul T Malpani, Abhishek Jain, Puneet Tomar, Ankit Singh Garg, Gaurav Indian J Ophthalmol Original Article PURPOSE: To provide real-world data on the world-wide-web for patient and doctor awareness. METHODS: From December 2017 to January 2020, consecutive patients with choroidal melanoma (CM), iris ciliary body melanoma (ICM), and ocular surface squamous carcinoma (OSSC) had specific outcomes recorded at each return visit. Each result was anonymized, entered in an online portal, and sent to a unique software program where it was used to create real-world data of number of patients, mean vision, local tumor control, eye salvage, systemic metastases, and length of follow-up for our eye cancer center. RESULTS: A HIPAA compliant, internet-based software program was developed and linked to public access web page to collect and analyze near-real-time data pertaining to the treatment, vision, life, and follow-up time of patients. During this period, CM radiation plaque tumor control was 99.7%, median vision 20/25 (mean 20/50) and eye salvage 95.8%. ICM tumor control was 99.1% and the median vision 20/20 (mean 20/20). OSSC tumor control was 100% and the most common vision was 20/20 (mean 20/25). Rates of primary enucleation as treatment were 4.2% for CM, 2.8% for ICM, and 0% for OSSC. All patient results were updated by the ophthalmic oncology fellow at each patient visit as to reflect near-real-time outcomes at our center. CONCLUSION: Prospective data collection of returning patients was found to be a simple method to reflect patient care outcomes. This method of reporting doctor outcomes offers a measure of transparency for patients and an opportunity to compare results with other clinical practices. Wolters Kluwer - Medknow 2021-01 2020-12-15 /pmc/articles/PMC7926100/ /pubmed/33323598 http://dx.doi.org/10.4103/ijo.IJO_257_20 Text en Copyright: © 2020 Indian Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Maheshwari, Abhilasha Finger, Paul T Malpani, Abhishek Jain, Puneet Tomar, Ankit Singh Garg, Gaurav Doctor reported outcomes: Real-world data from a tertiary eye cancer center |
title | Doctor reported outcomes: Real-world data from a tertiary eye cancer center |
title_full | Doctor reported outcomes: Real-world data from a tertiary eye cancer center |
title_fullStr | Doctor reported outcomes: Real-world data from a tertiary eye cancer center |
title_full_unstemmed | Doctor reported outcomes: Real-world data from a tertiary eye cancer center |
title_short | Doctor reported outcomes: Real-world data from a tertiary eye cancer center |
title_sort | doctor reported outcomes: real-world data from a tertiary eye cancer center |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926100/ https://www.ncbi.nlm.nih.gov/pubmed/33323598 http://dx.doi.org/10.4103/ijo.IJO_257_20 |
work_keys_str_mv | AT maheshwariabhilasha doctorreportedoutcomesrealworlddatafromatertiaryeyecancercenter AT fingerpault doctorreportedoutcomesrealworlddatafromatertiaryeyecancercenter AT malpaniabhishek doctorreportedoutcomesrealworlddatafromatertiaryeyecancercenter AT jainpuneet doctorreportedoutcomesrealworlddatafromatertiaryeyecancercenter AT tomarankitsingh doctorreportedoutcomesrealworlddatafromatertiaryeyecancercenter AT garggaurav doctorreportedoutcomesrealworlddatafromatertiaryeyecancercenter |